Table 2.
Effects After 2 and 3 anti-SARS-CoV-2 Vaccine Doses in MGUS Patients
| Two Doses | Three Doses | P Value | |
|---|---|---|---|
| Vaccine sequence in SARS-CoV-2-positive MGUS pts, n | BNT162b2 mRNA × 2, 31 ChAdOx1 nCoV-19 × 2, 9 mRNA-1273 × 2, 2 |
BNT162b2 mRNA × 3, 28 ChAdOx1 nCoV-19 × 2/mRNA-1273, 7 BNT162b2 mRNA × 2/mRNA-1273, 4 ChAdOx1 nCoV-19 × 2/BNT162b2 mRNA, 3 mRNA-1273 × 2/BNT162b2 mRNA, 2 |
NA |
| SARS-CoV-2 infection, n (%) | 42/156 (26.9) | 44/904 (4.9) | <0.001 |
| COVID-19 outcome | |||
| Presence of symptoms, n (%) | 17/42 (40.5) | 6/44 (13.6) | 0.007 |
| Hospitalization, n (%) | 0 | 2 (4.5) | NA |
| Hospitalization in ICU, n (%) | 0 | 1 (2.3) | NA |
| Death due to COVID-19, n (%) | 0 | 1 (2.3) | NA |
| Mean number of days from last vaccine dose to SARS-CoV-2 infection, ±SD (range) | 47.3 ± 41.9 (2–245) | 171 ± 60.8 (2–285) | <0.001 |
ICU = intensive care unit; MGUS = monoclonal gammopathies of undetermined significance; NA = not applicable; pts = patients.